Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
Saved in:
| Title: | Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol. |
|---|---|
| Authors: | Toksvang LN; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark. Linea.natalie.toksvang@regionh.dk., Als-Nielsen B; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark., Bacon C; St. James Hospital, Dublin, Ireland., Bertasiute R; Vilnius University Hospital Santariskiu Klinikos, Vilnius, Lithuania., Duarte X; Instituto Português de Oncologia Lisboa Francisco Gentil Departamento de Pediatria, Lisbon, Portugal., Escherich G; University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Helgadottir EA; Landspitali University Hospital, Reykjavik, Iceland., Johannsdottir IR; Oslo University Hospital, Oslo, Norway., Jónsson ÓG; Landspitali University Hospital, Reykjavik, Iceland., Kozlowski P; Örebro University Hospital, Örebro, Sweden., Langenskjöld C; Drottning Silvias Barnsjukhus, Gothenburg, Sweden., Lepik K; Tallinn Children's Hospital, Tallinn, Estonia., Niinimäki R; Oulu University Hospital and PEDEGRO Research Unit, University of Oulu, Oulu, Finland., Overgaard UM; Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark., Punab M; Tartu University Hospital, Tartu, Estonia., Räty R; Helsinki University Central Hospital, Helsinki, Finland., Segers H; Leuvens Kanker Instituut (LKI), KU Leuven - UZ Leuven, Leuven, Belgium., van der Sluis I; Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands., Smith OP; Our Lady's Children Hospital, Dublin, Ireland., Strullu M; Université de Paris, hôpital universitaire Robert-Debré (APHP), Paris, France., Vaitkevičienė G; Center for Pediatric Oncology and Hematology, Vilnius University, Vilnius, Lithuania., Wik HS; Oslo University Hospital, Oslo, Norway., Heyman M; Karolinska Institutet, Stockholm, Sweden.; Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden., Schmiegelow K; Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen, Denmark.; University of Copenhagen, Copenhagen, Denmark. |
| Source: | BMC cancer [BMC Cancer] 2022 May 02; Vol. 22 (1), pp. 483. Date of Electronic Publication: 2022 May 02. |
| Publication Type: | Clinical Trial Protocol; Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1471-2407 |
|---|---|
| DOI: | 10.1186/s12885-022-09522-3 |
